Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A4GQ
|
|||
| Drug Name |
Tisotumab vedotin
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Approved | [1] | |
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 2 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [3], [4] | ||
| Company |
Seagen/Genmab
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Tissue factor (F3) | Target Info | . | [1] |
| KEGG Pathway | Complement and coagulation cascades | |||
| NetPath Pathway | IL4 Signaling Pathway | |||
| TGF_beta_Receptor Signaling Pathway | ||||
| TWEAK Signaling Pathway | ||||
| Panther Pathway | Angiogenesis | |||
| Blood coagulation | ||||
| Pathwhiz Pathway | Coagulation | |||
| Reactome | Extrinsic Pathway of Fibrin Clot Formation | |||
| WikiPathways | Complement and Coagulation Cascades | |||
| Formation of Fibrin Clot (Clotting Cascade) | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 761208. | |||
| REF 2 | ClinicalTrials.gov (NCT03245736) Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.. U.S. National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.